# US 2022/0044813 A1 · Individualized multiple-day simulation model of type 1 diabetic patient decision-making for developing, testing and optimizing insulin therapies driven by glucose sensors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0044813 A1
- Document ID: US20220044813A1
- Status: Published application
- Kind: A1
- Application number: 17/451,609
- Filed: 2021-10-20
- Published: 2022-02-10
- Earliest claimed: 2015-05-18
- Assignees: DexCom, Inc.
- Applicants: DexCom, Inc.
- Inventors: Martina Vettoretti; Andrea Facchinetti; Giovanni Sparacino; Claudio Cobelli
- Web page: https://patentgrep.com/patent/US20220044813A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- G16H 20/17: delivered via infusion or injection
- G16H 40/60: for the operation of medical equipment or devices
- G16H 50/50: for simulation or modelling of medical disorders
- A61M 2205/50: with microprocessors or computers
- A61M 2230/005: Parameter used as control input for the apparatus
- A61M 2230/201: Glucose concentration
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors. Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

## Claims

### Claim 1

A method for providing a real-time therapeutic recommendation for use in type 1 diabetes management in a patient, comprising:
inputting, to a decision support module, data including continuous glucose monitoring data obtained from a glucose sensor, insulin pump data, and other diabetes management data;
generating, based on the input data, a first therapeutic recommendation;
displaying the therapeutic recommendation to a patient;
inputting, to the decision support model, data indicative of an action taken by the patient in response to receiving the displayed therapeutic recommendation, the data including continuous glucose monitoring data obtained from the glucose sensor and insulin pump data; and
generating, based on the input data and the data indicative of an action taken by the patient, a second therapeutic recommendation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the continuous glucose monitoring data is selected from the group consisting of a glucose concentration trend, a predicted glucose concentration, a number of past hyperglycemic events, and a number of past hypoglycemic events.

### Claim 3 (depends on 1)

The method of claim 1, wherein the other diabetes management data is selected from the group consisting of meal data and physical exercise data.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first therapeutic recommendation or the second therapeutic recommendation is selected from the group consisting of a recommended insulin dose and a basal insulin change.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first or second therapeutic recommendation is delivered through a smartphone notification.

### Claim 6 (depends on 1)

The method of claim 1, wherein the decision support module compares the data indicative of an action taken by the patient responsive to the first therapeutic recommendation to determine if the patient has taken the therapeutic recommendation, has ignored the therapeutic recommendation, or has taken an action similar to the therapeutic recommendation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the action taken by the patient is employed to modify a decision-making module configured to simulate real-life situations and everyday patient behaviors, wherein the decision-making module utilizes self-monitored blood glucose data measurement errors, continuous glucose monitoring data measurement errors, miscalculations of meal carbohydrate content, early insulin administration errors, delayed insulin administration errors, and missed insulin bolus errors.

### Claim 8 (depends on 7)

The method of claim 7, wherein the decision-making module utilizes patient data to assess glycemic control or efficacy of the decision support module, or to suggest modifications to the decision support module to improve its performance.
